Document:

Exhibit 10.14

                              CONSULTING AGREEMENT

         This Consulting Agreement ("Agreement") is made effective this 1st day
of January, 2003 ("Effective Date") by and between ProUroCare, Inc. ("Client"),
located at One Carlson Parkway., Suite 124, Plymouth, MN 55447 and Dr. Neal
Shore, ("Consultant") located at Myrtle Beach, SC.

         WHEREAS, Client is a Minnesota Corporation based in Minnesota in the
business of developing and manufacturing equipment for medical applications that
wishes to engage the Consultant to provide services in support of this effort,
and

         WHEREAS, Consultant is an independent contractor who has expertise in
providing urology based medical services and expertise in conducting in
assessment, clinical utility and general medical practice related to the use of
various urology based medical devices related to the Clients core business, and
who wishes to provide consulting services to Client in this respect, and

         WHEREAS, the Parties to this Agreement, wanting to set forth their
mutual understanding with respect to the terms and conditions of this
engagement, hereby set forth the terms of their agreement as follows:

1.     Consultant shall assist Client in selected assignments as agreed to by
       both Parties on terms that are mutually agreed as appropriate for each
       assignment. These scope and terms of each assignment shall be set forth
       in writing either in the body of this document or as an attachment
       thereto.

2.     The services required under this Agreement shall be performed at the
       offices of the Consultant or at such other locations as may be from time
       to time agreed to by the Parties. Consultant shall be responsible for
       establishing his working hours, and work methods as may be appropriate
       for performing the services under this Agreement,

3.     Consultant shall provide all of the equipment, including computers, and
       office space needed to furnish services under this Agreement provided
       that if additional clinical trials are necessary, the Client would
       provide certain systems to the Consultant to use for such activities.

4.     Consultant shall keep Client advised of his activities pursuant to this
       Agreement and shall furnish written reports of all work performed.

5.     The Term of this Agreement shall be from the Effective Date for a unknown
       period of time, and the Agreement may be terminated by either party at
       any time.

6.     At all times Consultant shall serve as an independent contractor and not
       as an employee of the Client. Consultant shall be required to pay all
       income or employment taxes that are required of him as an independent
       contractor and shall absolve Client from any responsibility in regard to
       Consultant's taxes.
<PAGE>

7.     It is the intent of the Parties that Consultant be compensated as per the
       Attachment A to this agreement which is hereby incorporated into this
       agreement. In addition to the compensation as per Attachment A, the
       Client shall pay Consultant all reasonable and necessary out of pocket
       business expenses incurred in the performance of services to the extent
       that the scope and amount are agreed to by Client in writing prior to the
       expense being incurred. The current assignment is set forth in Attachment
       A, as it may be from time to time updated, which attachment is hereby
       incorporated into and made a part of this Agreement.

8.     The work product developed by Consultant in the course of performing this
       Agreement shall be deemed Confidential and become the property of the
       Client and shall be returned to Client at the end of the term of this
       Agreement.

9.     Consultant agrees that any inventions, discoveries, improvements and
       ideas (whether or not they are in writing or reduced to practice) or
       works of authorship (whether or not they can be patented or copyrighted)
       that Consultant makes, authors, or conceives and that concern the Medical
       Device shall be the property of the Company and he or she hereby assigns
       all rights thereto to the Company. Consultant shall take all reasonable
       steps as may be requested by the Company to effectuate the intent of the
       foregoing sentence, including the execution of appropriate documents of
       assignment. Consultant hereby represents that neither Consultant nor his
       or her staff have any rights under, and will make no claims against the
       Company with respect to, any invention, discoveries, improvements and
       ideas or works of authorship which relate to the Medical Device.

10.    Proprietary Information.

                  (a) Consultant acknowledges that he or she shall receive
       information from the Company that is the confidential property of the
       Company. At all times, both during the term of this Agreement and after
       its termination, Consultant shall keep in strictest confidence and trust
       all Confidential Information (as defined below), and shall not use,
       disclose or reproduce, or cause or permit the use, disclosure or
       reproduction of, any such Confidential Information without the prior
       written consent of the Company. Consultant shall require that all of his
       staff members who are involved with the Study agree to the same
       confidentiality provisions as are contained herein. For purposes of this
       Agreement, "Confidential Information" shall mean the results of the Study
       and all other information to which Consultant gains access during the
       term of this Agreement that is marked or designated as confidential by
       the Company or which Consultant should reasonably understand from the
       context to be confidential, but will not include any information which is
       or becomes publicly available through no fault of Consultant. Upon
       termination of this Agreement or at any time the Company so requests,
       Consultant shall deliver to the Company all notes, memoranda, notebooks,
       drawings or other documents compiled by Consultant or delivered to
       Consultant containing any Confidential Information, including copies
       thereof, in his possession, it being agreed that such items and all
       Confidential Information contained therein are at all times the property
       of Company.
<PAGE>

                  (b) Consultant's obligations with respect to Confidential
       Information shall survive the termination of this Agreement, but
       Consultant's obligations with respect to any item of Confidential
       Information shall cease whenever Consultant can demonstrate that such
       Confidential Information (i) is or has become publicly known under
       circumstances not involving any direct or indirect breach of this
       Agreement or other misconduct attributable to Consultant, (ii) was
       lawfully known by Consultant prior to communication of such Confidential
       Information to Consultant by the Company, or (iii) subsequently became
       known to Consultant from another source lawfully having possession of
       such Confidential Information and lawfully entitled to disclose such
       Confidential Information to Consultant without any direct or indirect
       breach of any obligation of confidentiality.

                  (c) Consultant hereby acknowledges and agrees that any breach
       of his obligations under Sections 9 and 10 would cause the Company
       irreparable injury and damage which cannot be reasonably or adequately
       compensated by money damages and, therefore, Consultant expressly agrees
       that the Company shall be entitled to injunctive or other equitable
       relief to prevent a breach of Sections 9 and 10, in addition to any other
       remedies available to the Company.

11.      Exclusive Arrangement

       (a) Consultant hereby represents to and agrees with the Company that he
       or she does not now, and shall not during the term of this Agreement,
       participate in a clinical study or otherwise be involved in connection
       with the development of any other product for mechanical imaging of the
       prostate.

       (b) Consultant hereby acknowledges and agrees that this Section 11 is
       reasonable and necessary to ensure that the Company receives the expected
       benefits of Consultant's expertise and that any breach of Consultant's
       obligations under this Section 11 would cause the Company irreparable
       injury and damage which cannot be reasonably or adequately compensated by
       money damages and, therefore, Consultant expressly agrees the Company
       shall be entitled to injunctive or other equitable relief to prevent a
       breach of this Section 11, in addition to any other remedies available to
       the Company, and that the duration of the period referred to in Section
       11 (a) above shall be extended beyond its then scheduled termination date
       for a period equal to the duration of the violation. If any provision or
       application of this Section 11 shall be held unlawful or unenforceable in
       any respect, this Section 11 shall be revised or applied in a manner that
       renders it lawful and enforceable to the fullest extent possible.

12.     Consultant shall maintain in strict confidence all proprietary
        commercial or financial information of Client. This obligation shall
        remain in full force after the termination of this Agreement.

13.     All payments due Consultant under this Agreement shall be paid by Client
        within thirty (30) days of date in which entitlement is due. For out of
        pocket expenses entitlement shall occur upon pre-approval of such
        expense and presentation to Client by the Consultant of appropriate
        billing and back-up documentation.

14.     Consultant shall have no right to assign this Agreement to any other
        third party without the written consent of the Client.

15.     This Agreement shall be interpreted under the laws of the State of
        Minnesota.
<PAGE>

IN WITNESS WHEREOF, the parties hereto have caused this Consulting Agreement to
be executed as of the date and year first above written.

         CLIENT                                               CONSULTANT

         ProUroCare, Inc.                                     Dr. Neal Shore
         Mr. Todd Leonard
         President and COO

         BY Todd Leonard                                      BY Neal Shore
           -------------------                                ------------------
<PAGE>

                                  ATTACHMENT A

Overview:

Based on the status of the current product development at ProUroCare, we are
nearing both FDA filing and product launch of the Sensor Guided DRE(TM) into the
Urology base practice with expansion into general practitioner's and internist's
offices. This process necessitates the expansion and further development of our
medical expertise. Your involvement with the Company through our clinical trials
and input into our product development has been instrumental and helpful to us
in positioning the SGDRE(TM) for the next phases of product development.

As we move towards product release, we would like to formalize your position
with us as consulting Medical Director. This function is envisioned in the
following tasks:

Overview of Tasks:

      I.    Physician and clinic assessment and recruitment - over the next 6
            months, ProUroCare will be identifying urology practices that are
            similar in size and patient population to Grand Strand Urology. Your
            assistance in both the identification and communication with such
            groups will be required from time to time.

      II.   Clinical Protocol Review - from time to time, ProUroCare will need
            to develop clinical protocols. We will be asking for your assistance
            from time to time to assess the protocols for clinical merit and
            relevance.

      III.  Representation of the Company at Key Meetings - ProUroCare continues
            to schedule meetings with the FDA, various physicians and key
            investors. From time to time, the Company may ask you to participate
            in such meetings in person or by telephone to discuss your medical
            opinion of Company products, their use, functionality and
            application to the urology marketplace.

      IV.   Technical Due Diligence for the Company - The Company is currently
            pursuing various business relationships with a number of sources.
            You will be asked to be a technical representative of the Company to
            discuss ProUroCare's technology from your medical perspective with
            various groups conducting due diligence.

      V.    Facilitation of a Medical Advisory Board for the Company - It is
            anticipated that over the next few years the Company will expand its
            presence within the medical community at large by organizing a
            medical advisory board. From time to time you will be asked to
            participate in such activities.
<PAGE>

Proposed Compensation:

As a key member of our external consulting group we consider you an essential
part of the fabric of our Company. As such, we considered your participation as
consulting Medical Director to be comparable to our existing Board members when
it comes to compensation. Thus we would propose the following:

Options:          10,000 vested over two years at 5,000 shares per year for each
                  full year of participation. Options shall be priced at current
                  pricing and if the Company has an event in which the Company
                  is sold, prior to such time the stock options has vested, the
                  outstanding options shall be prorated on a monthly basis and
                  you shall be issued the options due at that time on such
                  prorate basis.

Payment:    A.    Annual Compensation - $7500 per year of participation for your
                  participation in all activities pertaining to the tasks listed
                  on page one of this Attachment A of this agreement- not to
                  exceed more than 60 hours.

            B.    Consultation Fee- beyond the responsibilities identified on
                  page one of this Attachment A, there may be additional
                  projects or additional hours beyond the 60 hours per year in
                  which you may choose to participate in from time to time.
                  Payment of an hourly fee of $250/hour for services rendered on
                  a project by project basis. Such projects shall be presented
                  to you in written form prior to the commencement of any such
                  project and shall have specific start and stop points. Note
                  that any travel on behalf of the Company you may do will be
                  calculated at a rate of $2500 per each full day of travel.

            C.    Expense Reimbursement - all reasonable out of pocket expenses
                  you have when conducting your services as consulting Medical
                  Director shall be covered by us.

            D.    If at any time during the next 6 months you provide the
                  Company with a qualified investor that actually makes an
                  investment in the Company, Shore Holdings, LLC, shall be
                  entitled to warrants equal to 2.5% of the investment made by
                  such investor at a price equal to the price paid per share
                  paid by such an investor at the time of such investment.
                  Warrants shall carry a five year expiration date from date of
                  issuance.

         CLIENT                                      CONSULTANT

         Todd Leonard                                Neal Shore
         ---------------------------                 ---------------------------
         ProUroCare, Inc.                            Dr. Neal Shore
         Todd E. Leonard
         President and COO
<PAGE>

2004 Compensation:

As a key member of our external consulting group we consider you an essential
part of the fabric of our Company. As such, we are amending the original
Consulting Agreement to with this attachment which reflects compensation for
your services to ProUroCare in 2004.

Payment:    A.    Annual Compensation - $15,000 per year of participation for
                  your participation in all activities pertaining to the tasks
                  listed on page one of this Attachment A of this agreement- not
                  to exceed more than 60 hours.

            B.    Consultation Fee- beyond the responsibilities identified on
                  page one of this Attachment A, there may be additional
                  projects or additional hours beyond the 60 hours per year in
                  which you may choose to participate in from time to time.
                  Payment of an hourly fee of $250/hour for services rendered on
                  a project by project basis. Such projects shall be presented
                  to you in written form prior to the commencement of any such
                  project and shall have specific start and stop points. Note
                  that any travel on behalf of the Company you may do will be
                  calculated at a rate of $2500 per each full day of travel.

            C.    Expense Reimbursement- all reasonable out of pocket expenses
                  you have when conducting your services as consulting Medical
                  Director shall be covered by us.

         CLIENT                                               CONSULTANT

         Michael P. Grossman                                  Neal Shore
         ----------------------------------------             ------------------
         ProUroCare, Inc.                                     Dr. Neal Shore
         Michael P. Grossman
         President and CEOLETTER OF UNDERSTANDING

                                 ProUroCare Inc.
                            One Carlson Parkway North
                                    Suite 124
                               Plymouth, MN 55447

                                 March 23, 2004

Profile, LLC
c/o Mr. Stan Graves
2700 Corporate Drive, Suite 120
Birmingham, Alabama  35242

with a copy to:

Peter C. Quittmeyer, Esq.
Sutherland, Asbill & Brennan, LLP
999 Peachtree Street, Suite 1900
Atlanta, GA  30309

Gentlemen:

         This letter sets forth the agreement between ProUroCare, Inc.
("ProUroCare"), and Profile, LLC ("Profile").

         Profile and ProUroCare have entered into the following agreements and
relationships:

      (a)   Stock Purchase Agreement, dated January 14, 2002, between Profile
            and ProUroCare, as amended on March 22, 2002 with a First Amendment
            to Stock Purchase Agreement (as amended the "Purchase Agreement").

      (b)   License Agreement between Profile and ProUroCare, dated January 14,
            2002, as amended on March 22, 2002 with a First Amendment to License
            Agreement (as amended, the "License").

      (c)   Amended and Restated Shareholder Control and Share Transfer
            Agreement between ProUroCare, Profile, Clinical Network, Inc.,
            Clinical Network, LLC, and CS Medical Technologies, LLC dated
            January 14, 2002 (the "Shareholder Agreement").

      (d)   Profile owns 1,333,333 shares of common stock of ProUroCare.

      (e)   Profile has given notice to ProUroCare that it is in default under
            the License and ProUroCare has denied that it is in default.
<PAGE>

March 23, 2004
Page 2

      (f)   ProUroCare held a special Shareholders' Meeting on March 5, 2004, at
            which the shareholders of ProUroCare approved the merger of
            ProUroCare with GIC Acquisition Corp. ("GIC"), a subsidiary of
            Global Internet Communications, Inc. ("Global") whereby the
            shareholders of ProUroCare will exchange their shares of ProUroCare
            common stock for shares of Global common stock (the "Merger") all as
            described in the Private Placement Memorandum (hereinafter defined).

      (g)   On March 3, 2004, Profile exercised the dissenters' rights on behalf
            of beneficial owners owning 308,465 shares of common stock of
            ProUroCare.

      (h)   Global is engaged in a private placement of a minimum of 1,500,000
            shares of Global common stock and a maximum of 2,500,000 shares of
            Global common stock at $2.00 per share pursuant to a private
            placement memorandum dated February 11, 2004, as supplemented by
            Supplement No. 1, dated March 23, 2004 (the "Private Placement") (as
            so supplemented, the "Private Placement Memorandum").

      (i)   Maurice R. Taylor, II, ("Taylor") owns beneficially approximately
            1,041,315 shares of common stock of ProUroCare. Of these shares,
            847,982 shares of ProUroCare common stock are owned by Clinical
            Network, LLC, and 85,000 shares of ProUroCare common stock are owned
            by Clinical Network, Inc. Taylor's ownership also includes 108,333
            shares that are subject to options. Based on Taylor's ownership in
            Clinical Network, LLC and Clinical Network, Inc., approximately
            589,815 shares of common stock of ProUroCare are owned beneficially
            by Taylor and his family. The remaining 342,302 shares of ProUroCare
            common stock owned by Clinical Network, LLC and Clinical Network,
            Inc. are owned beneficially by persons or entities that are not
            otherwise affiliated with Taylor.

         Based upon the preceding, the parties hereto agree as follows:

      1. All continuing obligations of ProUroCare to Profile under the Purchase
Agreement including, without limitation, Sections 4.2, 4.3 and 4.4, shall
terminate upon the Effective Date and shall be of no further force or effect
after the Effective Date (as hereinafter defined).

      2. The Shareholder Agreement shall terminate as of the Effective Date and
be of no further force or effect after the Effective Date, contingent only upon
Clinical Network, LLC, Clinical Network, Inc. and CS Medical Technologies, LLC
agreeing in writing to terminate the Shareholder Agreement.

      3. As of the Effective Date, Profile withdraws its default letters under
the License and waives any existing defaults under the License. This waiver
shall in no way limit the ability of Profile to enforce its rights and remedies
for defaults by ProUroCare occurring after to the Effective Date. For purposes
of Section 7.4(e) of the License, in the event of a termination of the License
after the Effective Date, Profile shall be obligated to return the number of
Global shares issued to ProUroCare in the proposed merger in respect of one-half
of the original 1,076,923 shares of ProUroCare stock acquired by Profile
pursuant to the Stock Purchase Agreement (subject to adjustment for any stock
splits or dividends or exchange ratios under the Merger).
<PAGE>

March 23, 2004
Page 3

      4. ProUroCare agrees that of the funds raised by Global in the Private
Placement not less than $1,200,000 will be used by ProUroCare in connection with
the research, development and commercialization of the "Devices" as that term is
defined in the License; provided, however, said amount may be reduced by any
amounts paid to Profile pursuant to Section 6 hereof and will be increased (to
the amount of such reduction from $1,200,000) to the extent ProUroCare raises
more than $3,000,000 in the Private Placement as provided in the Private
Placement Memorandum or in any subsequent financing.

      5. As of the Effective Date, Profile agrees to transfer to ProUroCare
300,000 shares of ProUroCare common stock.

      6. As consideration for the agreements of Profile contained in this
Agreement, ProUroCare shall pay Profile $750,000; $100,000 of which shall be
payable as of the Effective Date, $325,000 of which shall be payable ninety (90)
days months after the Effective Date, and the final $325,000 of which shall be
payable within six (6) months after the Effective Date. Profile will receive a
Promissory Note ("Note") for the remaining $650,000 outstanding as of the
Effective Date, which will accrue interest at the rate of six and one-half
percent (6 1/2 %) per year and, in the event of default in payment, will accrue
eight and one-half percent (8 1/2 %) after the payment default. ProUroCare may
prepay the Note at any time. The Note will be secured by the assets of
ProUroCare, including its intellectual property, in accordance with a security
agreement mutually acceptable to both parties, which shall be executed,
delivered and perfected immediately upon (and as a condition to) the Effective
Date. ProUroCare's counsel will prepare the Note, a security agreement, a
collateral patent assignment, an assignment of license and a UCC Financing
Statement to perfect Profile's security interest in ProUroCare's assets
(including its intellectual property), subject to approval by Profile's counsel,
not to be unreasonably withheld or delayed. ProUroCare shall cause said UCC
Financing Statements and Collateral Patent Assignments to be properly filed
immediately upon (and as a condition to) the Effective Date. Profile and
ProUroCare shall each pay its own attorneys' fees.

      7. The transfer of 300,000 shares of ProUroCare common stock, as of the
Effective Date, pursuant to this Agreement shall have the effect of settling any
dissenters' rights claims Profile or its beneficial owners have with respect to
the Merger or on account of Profile's exercise of dissenters' rights as
described in paragraph (g) above. The remaining 8,465 shares of ProUroCare
common stock for which dissenters' rights were exercised shall be returned to
Profile and shall participate in the Merger.
<PAGE>

March 23, 2004
Page 4

      8. As of the Effective Date, Taylor agrees that he will dispose of no
shares of ProUroCare common stock that he or his family beneficially owns so
long as any amounts are owing under the Note to Profile, including without
limitation any shares of ProUroCare common stock acquired in connection with the
exercise by Taylor or his family of any options or warrants to purchase shares
of ProUroCare common stock; provided, however, that in the event Clinical
Network, LLC or Clinical Network, Inc. distributes its shares to its beneficial
owners, then any person or entity not affiliated with Taylor may sell shares
that were previously owned by Clinical Network, LLC and Clinical Network, Inc.
and not be subject to these limitations; and, provided further, that Taylor may
sell up to 300,000 shares multiplied by a fraction, the denominator of which is
$750,000 and the numerator of which is the sum of the amount of principal under
the Note that has been paid by ProUroCare to Profile plus the original $100,000
paid on the Effective Date. For example, Taylor may sell 40,000 shares after
ProUroCare pays $100,000 to Profile, and Taylor may sell an additional 130,000
shares after ProUroCare makes its $325,000 payment to Profile. The foregoing
share totals are also subject to adjustment for any stock splits or dividends or
exchange ratios under the Merger. References in this Section 8 to ProUroCare
shares shall include any Global common stock received in exchange for such
ProUroCare shares.

      9. (a) Global shall prepare and file with the SEC, within 120 days after
the final closing of the Private Placement, a registration statement on Form
SB-2 with respect to resale of shares of Global common stock, including all
shares of Global common stock held by Profile or its transferees, from time to
time through the over-the-counter market or in privately negotiated
transactions, and use its commercially reasonable best efforts (subject to
receipt of necessary information from Profile or its transferees) to cause such
registration to be effective as soon as possible thereafter.

      (b) Global shall prepare and file such amendments and supplements to the
registration statement as may be necessary to keep such registration statement
effective for one year from its effective date or such shorter period when all
of Global common stock owned by Profile and its transferees have been sold or
may be sold pursuant to Rule 144(k).

      (c) Except to the extent an exemption from registration is available,
Global agrees to register or qualify the resale of such shares under all
applicable state securities or blue sky laws of such jurisdictions in the United
States as Profile or any transferee shall reasonably request, and to keep each
such registration or qualification effective during the period when such SEC
registration is required to be kept effective.

      (d) Upon request, Global will notify the shareholders whose shares are
being registered when the registration statement is filed with the SEC and each
state, and Global will notify all shareholders participating in the offering (A)
when the registration statement is effective (B) when any stop order is issued,
and (C) after such effectiveness, of the happening of any event as the result of
which the registration statement or the prospectus contains a material
misstatement or omission, and in the case of (B) or (C), Global will use its
best efforts, as soon as practicable, to cause the stop order to be lifted or
the registration statement and prospectus to be amended to correct the problem.

      (e) Global will pay all the costs and expenses of such registrations,
other than the legal fees of any shareholders' separate legal counsel, and any
commissions or fees relating to the sale of such shares, and will defend,
indemnify and hold the selling shareholder harmless for any liabilities and
actions in respect thereof which arise out of (i) any untrue or alleged untrue
statement of a material fact contained in such registration statement or
prospectus (other than information furnished by the shareholders for inclusion
therein), (ii) any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading, or (iii)
any violation of any law, rule or regulation in connection with such
registration, registration statement or prospectus.
<PAGE>

March 23, 2004
Page 5

      (f) During the period commencing on the date hereof and ending one year
following the effective date of the registration statement in which the Global
shares of Profile are registered as described in Section 9(a) above, if Global
effects any underwritten offering of common stock, and if such offering includes
any shares of Global common stock owned by any Global shareholder, then Global
will allow Profile and its transferees to participate in the offering by giving
Profile at least ten (10) days' prior notice. In the event that the managing
underwriter notifies Global in writing that the inclusion of the shares
requested to be so included by Profile and any other Global shareholders
permitted to participate would materially interfere with the underwriters'
ability to effectuate the registration and complete the offering, then the
number of shares of Global common stock of Profile and its transferees to be
included in the offering may be cut-back pro rata (based on the number of shares
of Global common stock requested by Profile and its transferees to be included
in the offering in relation to the total number of shares of Global common stock
requested by all Global shareholders to be included in the offering); provided
that, in no event, shall the cut-back for Profile and its transferees be any
less favorable than the cut-back for any other Global shareholder.

      (g) Global will take such other actions at its expense as are customary or
reasonably requested by the participating shareholder to facilitate the
registration and sale of shares contemplated by this Section 9.

      10. As of the Effective Date, ProUroCare and Profile will each, for
themselves and for their agents, administrators, employees, officers, directors,
shareholders, subsidiaries, affiliates, successors and assigns, release and
forever discharge the other and its past, present, and future officers,
directors, attorneys, insurers, principals, agents, servants, representatives,
employees, shareholders, subsidiaries, affiliates, partners, predecessors,
successors and assigns of and from all past, present and future claims, demands,
obligations, actions and causes of action, at law or in equity, whether under
statute, common law, or otherwise, of whatsoever kind or nature, from the
beginning of time to the Effective Date, except for obligations of the parties
contained in this Agreement. The release of ProUroCare shall expressly apply to
Stanley Graves and Dr. Teo F. Dagi and the release of Profile shall expressly
apply to Maurice R. Taylor, II, David F. Koenig and Alex Nazarenko.
Notwithstanding any of the foregoing to the contrary, the release of ProUroCare
shall not apply to Todd Leonard. This mutual release does not go into effect
with respect to existing claims of the parties against each other, if any, until
the Effective Date. Notwithstanding any of the foregoing to the contrary, except
as expressly set forth in Section 3 hereof, the foregoing release shall not
apply to the rights and obligations of the parties under the License.
<PAGE>

March 23, 2004
Page 6

      11. Profile is entering into this Agreement in reliance upon the
information disclosed in the Private Placement Memorandum. Profile has received
a copy of the Private Placement Memorandum. In the event that the Private
Placement Memorandum is again supplemented in any material respect prior to the
Effective Date, ProUroCare will cause Profile to receive such supplement in a
timely fashion and, if the changes disclosed in such supplement have a material
and adverse effect on Profile's position, Profile shall have the right, at its
option, to declare this letter of understanding to be of no force or effect and
void ab initio.

      12. This Agreement has been duly authorized, executed and delivered by
ProUroCare and as of the Effective Date will be binding upon and enforceable
against ProUroCare and, to the extent applicable, Global in accordance with its
terms. The Effective Date will not occur unless Global agrees (a) to meet its
obligations under the Agreement, (b) to cause ProUroCare to meets its
obligations under this Agreement, (c) to provide any necessary support,
including financial support, for ProUroCare to meet its obligations to Profile
under the Agreement and (d) to provide sufficient resources to ProUroCare in
such a manner that ProUroCare complies with Section 302A.551 of the Minnesota
Business Corporation Act with respect to the redemption of 300,000 shares of
common stock pursuant to Section 5 hereof and payment of the amounts set forth
in Section 6 hereof.

      13. The consummation of the transactions contemplated by this Agreement is
contingent upon (i) Global raising not less than $3,000,000 in the Private
Placement, (ii) the Merger being consummated, and (iii) the execution, delivery
and, as applicable, perfection of the instruments referenced in Section 6 and
payment of the first installment of $100,000 as contemplated therein. These
events shall occur no later than April 30, 2004 (the "Effective Date") and the
transactions contemplated herein shall be effective as of the Effective Date.
The parties agree in the event the conditions (i) and (ii) contained in this
Section are not met by April 30, 2004, then all the representations and
agreements contained herein shall be of no further force or effect and nothing
herein contained will be further binding on the parties, and this entire
Agreement shall be void ab initio.

      14. The agreements contained herein are meant to be binding agreements of
and enforceable against the parties hereto, their successor and assigns.

      15. Reference to shares of ProUroCare contained herein shall be to shares
of Global exchanged for ProUroCare shares as of the Effective Date, subject to
adjustment pursuant to Section 8. All rights of Profile under this Agreement
shall inure to the benefit of Profile's direct and indirect transferees.
References to Global shall, as the context may require, include any successor or
assign of Global or ProUroCare or their respective business, and any parent
corporation or affiliate whose shares may be exchanged for ProUroCare or Global
shares.

      16. This Agreement may be executed in any number of counterparts, each of
which when so executed and delivered will be deemed an original, and all of
which together shall constitute one and the same agreement.
<PAGE>

      If the foregoing sets forth your understanding, please so acknowledge by
signing a copy of this letter and returning it to the undersigned.

PROUROCARE INC.

By       Michael P. Grossman
   -------------------------------------------------
     Its                   Chief Executive Officer
         -------------------------------------------

Agreed and accepted this 23rd day of March, 2004

PROFILE, L.L.C.

By       Stanley Graves
   -----------------------------------------
     Its                   Manager
         --------------------------------------------

Agreed and accepted this 23rd day of March, 2004

Agreed and accepted this 23rd day of March, 2004
Solely for the purpose of agreeing to Sections 8 hereof:

         Maurice R. Taylor, II
-----------------------------------------------------
Maurice R. Taylor, II

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]